6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Common O
adverse O
reactions O
in O
healthy O
adult O
subjects O
( O
> O
=1.5 O
% O
) O
were O
: O
rash O
, O
pain O
in O
extremity O
, O
pruritus O
, O
and O
somnolence O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-888-825-5249 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
of O
raxibacumab O
has O
been O
studied O
only O
in O
healthy O
volunteers O
. O

It O
has O
not O
been O
studied O
in O
patients O
with O
inhalational O
anthrax O
. O

The O
safety O
of O
raxibacumab O
has O
been O
evaluated O
in O
326 O
healthy O
subjects O
treated O
with O
a O
dose O
of O
40 O
mg/kg O
in O
3 O
clinical O
trials O
: O
a O
drug O
interaction O
trial O
with O
ciprofloxacin O
( O
Study O
1 O
) O
, O
a O
repeat-dose O
trial O
of O
20 O
subjects O
with O
the O
second O
raxibacumab O
dose O
administered O
> O
=4 O
months O
after O
the O
first O
dose O
( O
Study O
2 O
) O
, O
and O
a O
placebo-controlled O
trial O
evaluating O
single O
doses O
with O
a O
subset O
of O
subjects O
receiving O
2 O
raxibacumab O
doses O
14 O
days O
apart O
( O
Study O
3 O
) O
. O

Raxibacumab O
was O
administered O
to O
86 O
healthy O
subjects O
in O
Study O
1 O
. O

In O
Study O
3 O
, O
240 O
healthy O
subjects O
received O
raxibacumab O
( O
217 O
received O
1 O
dose O
and O
23 O
received O
2 O
doses O
) O
and O
80 O
subjects O
received O
placebo O
. O

The O
overall O
safety O
of O
raxibacumab O
was O
evaluated O
as O
an O
integrated O
summary O
of O
these O
3 O
clinical O
trials O
. O

Of O
326 O
raxibacumab O
subjects O
, O
283 O
received O
single O
doses O
, O
23 O
received O
2 O
doses O
14 O
days O
apart O
, O
and O
20 O
received O
2 O
doses O
more O
than O
4 O
months O
apart O
. O

The O
subjects O
were O
18 O
to O
88 O
years O
of O
age O
, O
53 O
% O
female O
, O
74 O
% O
white O
, O
17 O
% O
black/African O
American O
, O
6 O
% O
Asian O
, O
and O
15 O
% O
Hispanic O
. O

Adverse O
Reactions O
Leading O
to O
Discontinuation O
of O
Raxibacumab O
Infusion O
Four O
subjects O
( O
1.2 O
% O
) O
had O
their O
infusion O
of O
raxibacumab O
discontinued O
for O
adverse O
reactions O
: O
2 O
subjects O
( O
neither O
of O
whom O
received O
diphenhydramine O
premedication O
) O
due O
to O
urticaria B-OSE_Labeled_AE
( O
mild O
) O
, O
and O
1 O
subject O
each O
discontinued O
for O
clonus B-OSE_Labeled_AE
( O
mild O
) O
and O
dyspnea B-OSE_Labeled_AE
( O
moderate O
) O
. O

Most O
Frequently O
Reported O
Adverse O
Reactions O
The O
most O
frequently O
reported O
adverse O
reactions O
were O
rash B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
. O

Table O
3 O
. O

Adverse O
Reactions O
Reported O
in O
> O
=1.5 O
% O
of O
Healthy O
Adult O
Subjects O
Exposed O
to O
Raxibacumab O
40 O
mg/kg O
IV O
Preferred O
Term O
Placebo O
N O
= O
80 O
( O
% O
) O
Single-dose O
Raxibacumab O
N O
= O
283 O
( O
% O
) O
Double-dose O
Raxibacumab O
> O
=4 O
Months O
Apart O
N O
= O
20 O
( O
% O
) O
Double-dose O
Raxibacumab O
2 O
Weeks O
Apart O
N O
= O
23 O
( O
% O
) O
Total O
Raxibacumab O
Subjects O
N O
= O
326 O
( O
% O
) O
Rash B-OSE_Labeled_AE
/ O
Rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
/ O
Rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
1 O
( O
1.3 O
) O
9 O
( O
3.2 O
) O
0 O
0 O
9 O
( O
2.8 O
) O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
1 O
( O
1.3 O
) O
7 O
( O
2.5 O
) O
0 O
0 O
7 O
( O
2.1 O
) O
Pruritus B-OSE_Labeled_AE
0 O
7 O
( O
2.5 O
) O
0 O
0 O
7 O
( O
2.1 O
) O
Somnolence B-OSE_Labeled_AE
0 O
4 O
( O
1.4 O
) O
0 O
1 O
( O
4.3 O
) O
5 O
( O
1.5 O
) O
Rashes O
For O
all O
subjects O
exposed O
to O
raxibacumab O
in O
clinical O
trials O
, O
the O
rate O
of O
rash B-OSE_Labeled_AE
was O
2.8 O
% O
( O
9/326 O
) O
compared O
with O
1.3 O
% O
( O
1/80 O
) O
of O
placebo O
subjects O
. O

Mild O
to O
moderate O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
rashes I-OSE_Labeled_AE
were O
reported O
in O
22.2 O
% O
( O
6/27 O
) O
of O
subjects O
who O
did O
not O
receive O
diphenhydramine O
premedication O
compared O
to O
3.3 O
% O
( O
2/61 O
) O
of O
subjects O
who O
were O
premedicated O
with O
diphenhydramine O
in O
the O
ciprofloxacin/raxibacumab O
combination O
trial O
( O
Study O
1 O
) O
. O

In O
the O
placebo-controlled O
raxibacumab O
study O
where O
all O
subjects O
received O
diphenhydramine O
( O
Study O
3 O
) O
, O
the O
rate O
of O
rash B-NonOSE_AE
was O
2.5 O
% O
in O
both O
placebo- O
and O
raxibacumab-treated O
subjects O
. O

Less O
Common O
Adverse O
Reactions O
Clinically O
significant O
adverse O
reactions O
that O
were O
reported O
in O
< O
1.5 O
% O
of O
subjects O
exposed O
to O
raxibacumab O
and O
at O
rates O
higher O
than O
in O
placebo O
subjects O
are O
listed O
below O
: O
* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
: O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
* O
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
: O
vertigo B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
: O
fatigue B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
* O
Investigations B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
amylase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
prothrombin B-OSE_Labeled_AE
time I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
: O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
: O
syncope B-OSE_Labeled_AE
vasovagal I-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
: O
insomnia B-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
: O
flushing B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
Immunogenicity O
The O
development O
of O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
raxibacumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
was O
evaluated O
in O
all O
subjects O
receiving O
single O
and O
double O
doses O
of O
raxibacumab O
in O
Studies O
1 O
, O
2 O
, O
and O
3 O
. O

Immunogenic B-NonOSE_AE
responses I-NonOSE_AE
against I-NonOSE_AE
raxibacumab I-NonOSE_AE
were I-NonOSE_AE
not I-NonOSE_AE
detected I-NonOSE_AE
in O
any O
raxibacumab-treated O
human O
subjects O
following O
single O
or O
repeat O
doses O
of O
raxibacumab O
. O

The O
incidence O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
immunogenicity O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
any O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
is O
highly O
dependent O
on O
several O
factors O
, O
including O
assay O
sensitivity O
and O
specificity O
, O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
raxibacumab I-NonOSE_AE
with O
the O
incidence O
of O
antibodies O
to O
other O
products O
may O
be O
misleading O
. O

